Study authors hypothesized that longer-acting testosterone replacement therapy will have significant impact on suppressing HPG axis compared with short-acting TRT preparations.
Overweight or obese men frequently have low serum testosterone concentrations, which is associated with increased risk of type 2 diabetes.
In a study, most symptomatic hypogonadal men treated with Natesto, a short-acting 4.5% nasal testosterone gel, attained normal testosterone levels at 6 months while preserving sperm counts.
Jatenzo® (testosterone undecanoate; Clarus Therapeutics), an oral testosterone replacement therapy, is now available for the treatment of hypogonadism.
The American College of Physicians has issued a set of recommendations to clarify the potential benefits and harms of testosterone therapy in men with age-related low testosterone.
Older men receiving testosterone treatment with higher waist-to-hip ratio experience greater increases in noncalcified coronary plaque volume.
For men with and without hypogonadism, testosterone therapy is associated with an increased short-term risk for venous thromboembolism.
More men with long-term opioid use are screened for low testosterone than men taking opioids for a short period of time; however, given the known link between opioid use and low testosterone, these rates were still lower than expected.
The increased opioid use has been associated with a rising incidence of opioid-induced endocrinopathy, most commonly in the form of androgen deficiency.
Long-term treatment with testosterone undecanoate was associated with reduced cardiovascular morbidity and mortality in patients with hypogonadism and type 2 diabetes.
Genetically low 25-hydroxyvitamin D levels are associated with lower testosterone levels.